Literature DB >> 20736392

Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index.

Ravi Suppiah1, Oliver Flossman, Chetan Mukhtyar, Federico Alberici, Bo Baslund, Denise Brown, Nadeem Hasan, Julia Holle, Zdenka Hruskova, David Jayne, Andrew Judge, Mark A Little, Peter A Merkel, Alessandra Palmisano, Philip Seo, Coen Stegeman, Vladimir Tesar, Augusto Vaglio, Kerstin Westman, Raashid Luqmani.   

Abstract

OBJECTIVES: To compare the Vasculitis Damage Index (VDI) with the Combined Damage Assessment Index (CDA) as measures of damage from vasculitis.
METHODS: A total of 283 patients with vasculitis from 11 European centres were evaluated in a cross-sectional study using the VDI and CDA.
RESULTS: Wegener's granulomatosis (58.4%) and microscopic polyangiitis (11.0%) were the most common diagnoses. Agreement between VDI and CDA scores (Spearman's correlation) was 0.90 (95% CI 0.87 to 0.92). There was good correlation between individual comparably evaluated organ systems (Spearman's correlation 0.70-0.94). Interobserver reliability (assessed by intraclass correlation coefficient (ICC)) was 0.94 (95% CI 0.89 to 0.98) for VDI and 0.78 (95% CI 0.63 to 0.93) for CDA. Intraobserver reliability was 0.92 (95% CI 0.83 to 1.00) for VDI and 0.87 (95% CI 0.75 to 1.00) for CDA. A total of 13 items were not used in the VDI compared to 23 in the CDA. Observers agreed that the CDA covered the full spectrum of damage attributable to vasculitis but was more time consuming and thus possibly less feasible for clinical and research purposes.
CONCLUSIONS: The VDI and CDA capture reliable data on damage among patients with vasculitis. The CDA captures more detail but is more complex and less practical than the VDI. Further evolution of damage assessment in vasculitis is likely to include key elements from both instruments.

Entities:  

Mesh:

Year:  2010        PMID: 20736392      PMCID: PMC4982462          DOI: 10.1136/ard.2009.122952

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  27 in total

1.  Wegener's granulomatosis: pathology and review of the literature.

Authors:  G C GODMAN; J CHURG
Journal:  AMA Arch Pathol       Date:  1954-12

2.  Damage occurs early in systemic vasculitis and is an index of outcome.

Authors:  A R Exley; D M Carruthers; R A Luqmani; G D Kitas; C Gordon; B A Janssen; C O Savage; P A Bacon
Journal:  QJM       Date:  1997-06

3.  Periarteritis nodosa; a critical review.

Authors:  P M ZEEK
Journal:  Am J Clin Pathol       Date:  1952-08       Impact factor: 2.493

4.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.

Authors:  A R Exley; P A Bacon; R A Luqmani; G D Kitas; C Gordon; C O Savage; D Adu
Journal:  Arthritis Rheum       Date:  1997-02

5.  The OMERACT filter for Outcome Measures in Rheumatology.

Authors:  M Boers; P Brooks; C V Strand; P Tugwell
Journal:  J Rheumatol       Date:  1998-02       Impact factor: 4.666

6.  Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa.

Authors:  L Guillevin; B Jarrousse; C Lok; F Lhote; J P Jais; D Le Thi Huong Du; A Bussel
Journal:  J Rheumatol       Date:  1991-04       Impact factor: 4.666

7.  Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients.

Authors:  M Gayraud; L Guillevin; P le Toumelin; P Cohen; F Lhote; P Casassus; B Jarrousse
Journal:  Arthritis Rheum       Date:  2001-03

8.  A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Authors:  David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey
Journal:  N Engl J Med       Date:  2003-07-03       Impact factor: 91.245

Review 9.  Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.

Authors:  A Knight; J Askling; F Granath; P Sparen; A Ekbom
Journal:  Ann Rheum Dis       Date:  2004-05-06       Impact factor: 19.103

10.  The future of damage assessment in vasculitis.

Authors:  Philip Seo; Raashid A Luqmani; Oliver Flossmann; Bernhard Hellmich; Karen Herlyn; Gary S Hoffman; David Jayne; Cees G M Kallenberg; Carol A Langford; Alfred Mahr; Eric L Matteson; Chetan B Mukhtyar; Tuhina Neogi; Abraham Rutgers; Ulrich Specks; John H Stone; Steven R Ytterberg; Peter A Merkel
Journal:  J Rheumatol       Date:  2007-06       Impact factor: 4.666

View more
  15 in total

Review 1.  Granulomatosis with polyangiitis in childhood.

Authors:  Marinka Twilt; Susanne Benseler; David Cabral
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

Review 2.  New-generation therapy for ANCA-associated vasculitis.

Authors:  David Jayne
Journal:  Clin Exp Nephrol       Date:  2013-09-07       Impact factor: 2.801

Review 3.  [Current guidelines on ANCA-associated vasculitides : Common features and differences].

Authors:  B Hellmich
Journal:  Z Rheumatol       Date:  2017-03       Impact factor: 1.372

4.  The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.

Authors:  Peter A Merkel; Sibel Z Aydin; Maarten Boers; Haner Direskeneli; Karen Herlyn; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Raashid A Luqmani
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

Review 5.  [ANCA-associated vasculitides : State of the art].

Authors:  B Hellmich
Journal:  Z Rheumatol       Date:  2019-08       Impact factor: 1.372

Review 6.  Granuloma in ANCA-associated vasculitides: another reason to distinguish between syndromes?

Authors:  Antje Mueller; Konstanze Holl-Ulrich; Wolfgang L Gross
Journal:  Curr Rheumatol Rep       Date:  2013-11       Impact factor: 4.592

7.  Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement.

Authors:  Bertha M Córdova-Sánchez; Juan M Mejía-Vilet; Luis E Morales-Buenrostro; Georgina Loyola-Rodríguez; Norma O Uribe-Uribe; Ricardo Correa-Rotter
Journal:  Clin Rheumatol       Date:  2016-02-06       Impact factor: 2.980

8.  Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Zachary S Wallace; Eli M Miloslavsky; Matthew Cascino; Sebastian H Unizony; Na Lu; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert Spiera; E William St Clair; Ulrich Specks; Paul Brunetta; Hyon K Choi; John H Stone
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-07       Impact factor: 4.794

9.  Evaluation of damage in giant cell arteritis.

Authors:  Tanaz A Kermani; Antoine G Sreih; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Paul A Monach; Larry Moreland; Christian Pagnoux; Philip Seo; Kenneth J Warrington; Steven R Ytterberg; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2018-02-01       Impact factor: 7.580

Review 10.  Issues in trial design for ANCA-associated and large-vessel vasculitis.

Authors:  Ruth M Tarzi; Justin C Mason; Charles D Pusey
Journal:  Nat Rev Rheumatol       Date:  2014-05-06       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.